Evercore ISI and BTIG Lower Abbott (ABT) Price Targets, Maintain Positive Ratings
Evercore ISI and BTIG have lowered their price targets for Abbott Laboratories (NYSE: ABT), while maintaining positive ratings (Outperform and Buy, respectively). Evercore ISI's adjustment to $134 from $138 was part of a Q1 medical tech preview, and BTIG's reduction to $131 from $140 followed an update to its model to include Exact Sciences and new data from Abbott's TriClip trial. Abbott Laboratories operates as a global healthcare company with four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
Abbott Laboratories (ABT) recently hit its 52-week low, prompting questions about its value as a healthcare bargain. While the Nutrition segment faces temporary headwinds, the Medical Devices division demonstrates strong, accelerating growth with market-leading innovations. Analysts maintain a "Moderate Buy" rating, suggesting the stock is undervalued and offers a compelling opportunity for long-term investors due to its reliable dividend and strategic acquisitions.
Abbott Laboratories stock: Trading at a discount amid steady growth potential
Abbott Laboratories (ABT) stock is currently trading at a discount, approximately 23% below fair value estimates, making it an attractive option for dividend-focused investors. The company boasts a diversified healthcare portfolio, robust financial health, and a strong dividend history with 54 consecutive years of increases. Despite some recent market pressures and revenue shortfalls, analysts maintain a positive outlook due to its innovation, operational consistency, and significant long-term growth potential from global demographic shifts and personalized medicine trends.
First patients treated in Pulse Biosciences (NASDAQ: PLSE) NANOPULSE-AF AFib trial
Pulse Biosciences has announced the enrollment and treatment of the first seven patients in its NANOPULSE-AF IDE pivotal clinical study for recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation. The study aims to enroll approximately 215 participants across the U.S. and Europe, evaluating procedural success and safety at 6 and 12 months post-ablation. This follows a successful feasibility trial that demonstrated high procedural success rates using the nPulse™ Cardiac Catheter System, which utilizes nanosecond pulsed field ablation energy.
Johnson & Johnson brings next-gen Varipulse PFA catheter to Europe
Johnson & Johnson has launched its Varipulse Pro system in Europe following CE mark approval. This next-generation pulsed field ablation (PFA) catheter features a new pulse sequence designed to improve procedural efficiency and reinforce safety and effectiveness. The technology offers a lower temperature profile and faster ablation while maintaining integration with the Carto 3 mapping system for precise lesion delivery.
Smart Insulin Management Devices Market is expected to Hit US$ 27.07 Billion by 2033 | Major Companies - Abbott, Medtronic, Tandem Diabetes Care, Inc., Eli Lilly and Company
The Smart Insulin Management Devices Market reached US$ 12.93 Billion in 2024 and is projected to grow to US$ 27.07 Billion by 2033, exhibiting an 8.6% CAGR during the forecast period. This growth is driven by advanced medical devices integrating insulin delivery with real-time monitoring and data analytics to optimize diabetes care. Key players include Abbott, Medtronic, and Eli Lilly, with significant industry developments in cloud-based AI analytics, bundled reimbursement programs, and closed-loop automated insulin delivery systems.
Bullish NeuroOne Medical Technologies Insiders Rewarded As Their Investment Rises To US$829.9k
Insiders at NeuroOne Medical Technologies Corporation saw their investments handsomely rewarded as the stock climbed 12% recently, increasing their original US$670.4k acquisition to US$829.9k. Chief Business Officer David Wambeke made the largest individual purchase of US$670k worth of shares at a price below the current market value. While total insider ownership is not exceptionally high, recent buying activity suggests optimism for the company's future despite it not being profitable in the last year.
Diabetes device recall surge reveals a worrying information gap
The article highlights a significant increase in diabetes device recalls, particularly for continuous glucose monitors (CGM) and insulin pumps, indicating a growing problem in the medical device industry. This surge in recalls suggests a concerning information gap related to the safety and efficacy of these essential medical devices. The report mentions specific Class I and Class II recalls in 2025 involving major companies like Abbott Laboratories, Tandem Diabetes Care, Dexcom, Medtronic, and Insulet Corp.
Stryker Corporation (SYK) stock price, news, quote and history
This article provides comprehensive financial information for Stryker Corporation (SYK), a medical technology company. It includes real-time stock data, historical performance, key financial metrics, earnings trends, and analyst insights. The company operates globally in medical devices, specializing in MedSurg, Neurotechnology, and Orthopaedics segments.
Executive pay, equity plan and auditor on ballot at Assertio (NASDAQ: ASRT) meeting
Assertio Holdings, Inc. (NASDAQ: ASRT) announced its virtual annual meeting on May 5, 2026, where stockholders will vote on several key proposals, including the election of six directors, expanding the 2014 Omnibus Incentive Plan share pool, an advisory vote on executive compensation, and ratification of Grant Thornton LLP as auditor. The proxy statement highlights the company's 2025 financial results, with $117.1 million in product sales and a non-GAAP adjusted EBITDA of $22.7 million, alongside details of its governance practices, ownership guidelines, and a clawback policy. The company emphasizes its commitment to aligning executive compensation with performance and stockholder interests.
Medical Foods Market Is Going to Boom |• Abbott • Danone
Worldwide Market Reports has released a comprehensive research study on the Medical Foods Market, forecasting significant growth between 2026 and 2033. The report analyzes key market drivers, challenges, opportunities, and restraints, providing insights into the competitive landscape, market segmentation, and regional trends. It aims to assist stakeholders in making informed investment decisions and understanding the future trajectory of the global Medical Foods market.
JBT Marel Has Fallen 27% From Its Highs. Is the Selloff a Buying Opportunity?
JBT Marel (JBTM) has experienced a 27% drop from its 52-week high, leading to questions about whether the selloff presents a buying opportunity. The company faces challenges such as projected tariff headwinds and integration complexity, but bulls are optimistic about the discounted integration story in a resilient market, backed by strong analyst targets and synergy realization. Investors are advised to watch the adjusted EBITDA margin when Q1 2026 results are reported, as it will be a key indicator for the company's future performance.
Rathbones Group PLC Increases Position in Abbott Laboratories $ABT
Rathbones Group PLC increased its stake in Abbott Laboratories (NYSE:ABT) by 3.6% in the fourth quarter, now owning 3,116,386 shares worth $390.45 million. Other hedge funds like Invesco Ltd., Alliancebernstein L.P., and Capital International Investors also significantly increased their holdings in ABT. The stock recently opened at $102.84, with a market capitalization of $179.11 billion, and analysts project 5.14 EPS for the current year.
Sowell Financial Services LLC Has $10.85 Million Position in AbbVie Inc. $ABBV
Sowell Financial Services LLC reduced its stake in AbbVie Inc. by 10.8% in the fourth quarter, selling 5,761 shares and ending with holdings valued at approximately $10.85 million. Despite insider sales totaling over $6 million, institutional investors own 70.23% of the stock. Analysts maintain a "Moderate Buy" consensus with an average target price of $253.15, while AbbVie recently beat Q4 EPS estimates and declared a $1.73 quarterly dividend.
Abbott Laboratories $ABT Holdings Reduced by Cidel Asset Management Inc.
Cidel Asset Management Inc. recently reduced its stake in Abbott Laboratories (NYSE:ABT) by 4.1% in the fourth quarter, selling 13,616 shares and now owning 322,225 shares. Despite this reduction, Abbott Laboratories remains the 7th largest position in Cidel's investment portfolio, representing 2.9% of its holdings. The article also details other institutional investor activities, recent insider transactions, analyst ratings, and the company's financial performance.
Abbott Laboratories $ABT Shares Acquired by BXM Wealth LLC
BXM Wealth LLC significantly increased its stake in Abbott Laboratories (NYSE:ABT) by 612.7% in the fourth quarter, bringing its total holdings to 28,772 shares valued at approximately $3.61 million. This move is part of a broader trend of institutional investors holding about 75% of Abbott's stock. Despite some trimmed price targets from Wall Street analysts, the consensus remains a "Moderate Buy" with an average target price of $135.68 following Abbott's Q4 earnings report, which met EPS estimates and guided for Q1 and FY2026.
Stereotaxis Announces FDA Clearance and Launch of Synchrony System
Stereotaxis (NYSE: STXS) has announced FDA 510(k) clearance for its Synchrony™ system, designed to modernize interventional cath labs with a 4K display, streamlined workflows, and an intuitive user interface. The system also includes SynX™, a cloud-based app enabling secure remote connectivity and collaboration. Stereotaxis anticipates over $3 million in revenue this year from Synchrony systems and views it as a foundational platform for future AI-enhanced innovations in digital surgery.
ABT SEC Filings - Abbott Labs 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Abbott Labs (ABT) SEC filings, including annual, quarterly, and material event reports, along with insider trading forms. It features AI-powered summaries to help investors quickly understand key points such as merger terms, benefit plan blackout periods, and executive compensation awards. The latest filings detail significant equity awards to Abbott executives and notes offerings to fund the acquisition of Exact Sciences Corporation.
Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now
Abbott Laboratories recently acquired Exact Sciences for $23 billion, integrating its cancer screening products like Cologuard and Oncotype DX into Abbott's diagnostics portfolio. This acquisition positions North American investors to gain exposure to the $60 billion U.S. cancer screening market through a diversified healthcare giant. The deal is expected to contribute $3 billion in incremental revenue to Abbott in 2026, despite an initial EPS dilution, and analysts generally view it positively for long-term growth.
Erste Group Keeps Their Hold Rating on Abbott Laboratories (ABT)
Erste Group has maintained a Hold rating on Abbott Laboratories (ABT). Despite this, the analyst consensus for Abbott Laboratories remains a Strong Buy with a significant upside, though some corporate insiders have been selling shares. The company recently reported its Q4 earnings with revenue of $11.46 billion and a net profit of $1.78 billion.
Erste Group Keeps Their Hold Rating on Abbott Laboratories (ABT)
Erste Group has reaffirmed its Hold rating on Abbott Laboratories (ABT), whose shares closed at $102.38. Despite this, the analyst consensus from TipRanks is a Strong Buy, with an average price target of $135.46 suggesting a 32.31% upside. The company recently reported quarterly revenues of $11.46 billion and a net profit of $1.78 billion.
Abbott (ABT) director Robert Alpern awarded 76 stock equivalent units as fees
Abbott Laboratories director Robert J. Alpern was granted 76 stock equivalent units on March 31, 2026, as part of his compensation. These units, valued at $102.67 each, track the performance of Abbott common shares and are credited to a grantor trust, generally paid out in cash upon retirement. This award brings his total balance to 10,544 stock equivalent units, including those from dividend reinvestment.
Abbott Stock Sits 26% Off Its Peak While Analysts Back a $132 Mean Price Target
Abbott Laboratories (ABT) stock is trading near its 52-week low, 26% off its peak, despite its recent $23 billion acquisition of Exact Sciences, which provides entry into the $60 billion U.S. cancer screening market, and strong growth in its FreeStyle Libre continuous glucose monitor business. Analysts show strong confidence with a mean price target of $132.28, implying a 28.6% upside, and TIKR's valuation model suggests the stock is undervalued given its growth prospects and free cash flow generation. The upcoming Q1 2026 earnings report will be a key test for post-acquisition execution and the performance of its new cancer diagnostics vertical.
Stryker Corporation (SYK) stock price, news, quote and history
This page provides a comprehensive overview of Stryker Corporation (SYK), a medical technology company. It includes current stock performance, historical data, financial metrics, and analyst insights. The company operates in MedSurg & Neurotechnology and Orthopaedics segments, offering a wide range of medical devices.
Analysts’ Top Healthcare Picks: Abbott Laboratories (ABT), Cogent Biosciences (COGT)
Two analysts have issued bullish sentiments on Abbott Laboratories (ABT) and Cogent Biosciences (COGT) within the Healthcare sector. Wells Fargo maintained a Buy rating for Abbott Laboratories with a $122.00 price target, while Guggenheim maintained a Buy rating for Cogent Biosciences and set a $45.00 price target. Both companies also received "Strong Buy" analyst consensus ratings with significant upside potential from current levels.
TD Cowen reiterates DexCom stock Buy rating on margin expansion outlook
TD Cowen has reiterated a Buy rating on DexCom Inc. (NASDAQ:DXCM) stock, setting an $84.00 price target, aligning with InvestingPro’s Fair Value, suggesting the stock is undervalued. The firm raised its estimates for 2026-2028, anticipating significant gross and operating margin expansion, while acknowledging recent concerns about a slowing U.S. continuous glucose monitoring market. DexCom recently surpassed Q4 2025 earnings and revenue expectations, and other firms like Evercore ISI, Canaccord Genuity, and Stifel have also issued positive ratings or adjusted price targets, with a Google executive appointed to its board.
ABT SEC Filings - Abbott Labs 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Abbott Labs (ABT) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It offers access to official disclosures with AI-powered summaries to help investors understand key points like merger terms, benefit plan blackout periods, and governance updates. Recent filings detail an insider stock acquisition, executive ownership, a board appointment, and the proposed acquisition of Exact Sciences.
Aberdeen Group plc Increases Holdings in Abbott Laboratories $ABT
Aberdeen Group plc increased its stake in Abbott Laboratories (ABT) by 1.2% in Q4, acquiring an additional 23,817 shares, bringing its total holding to 1,993,536 shares valued at approximately $249.8 million. Institutional investors now own about 75.18% of the company. Despite some insider selling, Director Daniel J. Starks bought 10,000 shares. Abbott reported Q4 EPS in line with expectations and issued Q1 and FY 2026 guidance, while analysts maintain a "Moderate Buy" rating with a consensus price target of $135.68.
What Abbott Laboratories (ABT)'s Oncology Test Integration Into OncoEMR Means For Shareholders
Abbott Laboratories recently integrated its Precision Oncology portfolio into Flatiron’s OncoEMR platform, allowing for digital ordering and result delivery of key oncology tests in over 1,600 U.S. community cancer centers. This integration is expected to enhance test utilization and streamline clinical workflows for Abbott (ABT), reinforcing its diagnostics segment. Despite potential benefits from this and other integrations like the Libre CGM data with Epic, the company still faces challenges such as margin pressure from tariffs and pricing in China and competitive pressures in diagnostics and diabetes care.
NEC Baby Formula Lawsuit & Settlement | April 2026 Update
This article provides an April 2026 update on NEC baby formula lawsuits against manufacturers like Abbott (Similac) and Mead Johnson (Enfamil). It details ongoing litigation in federal MDL and state courts, including recent trial outcomes, expert testimony challenges, and significant jury verdicts already awarded to plaintiffs. The piece highlights the scientific evidence linking cow milk-based formulas to necrotizing enterocolitis in premature infants and criticizes manufacturers for alleged failure to warn, indicating a shift in litigation strategy towards state courts after mixed results in federal bellwether cases.
Abbott Laboratories (ABT) director Nita Ahuja granted 102 stock equivalent units
Abbott Laboratories director Nita Ahuja was granted 102 stock equivalent units, valued at $102.67 each, as part of her board compensation. These units are credited to a stock equivalent unit account, mimicking the returns of Abbott common shares, and are typically paid in cash when she reaches 65 or retires from the board. This transaction resulted in her holding 102 stock equivalent units directly.
Nanoscope Therapeutics Names Former Alcon Exec as Its New COO
Nanoscope Therapeutics, a late-stage clinical biotechnology company, has appointed Paul Hallen as its new Chief Operating Officer. Hallen, with over three decades of ophthalmic experience, will oversee global operations as the company advances its MOGENRY gene therapy toward regulatory approval and commercialization. MOGENRY aims to restore vision for patients with severe retinal diseases like retinitis pigmentosa.
Abbott (ABT) director Gonzalez receives 321 stock equivalent units as fees
Abbott Laboratories director Patricia Paola Gonzalez received a grant of 321 Stock Equivalent Units as part of her director compensation. These units, valued at $102.67 each, track Abbott's common shares and are held in a grantor trust, increasing her total to 5,558 units. The units will be paid in cash upon her retirement or at age 65 and include amounts from a dividend reinvestment feature.
Director at Abbott (NYSE: ABT) receives stock equivalent unit award
Michael F. Roman, a director at Abbott (NYSE: ABT), received 367 stock equivalent units as part of his compensation. These units, which accrue dividends and are paid in cash typically upon retirement or at age 65, increased his total holdings to 6,283 units. This transaction was filed as a Form 4 and is considered a neutral event, as it is a compensation grant rather than an open-market purchase or sale.
Danaher Corp. Experiences Valuation Adjustment Amid Competitive Market Landscape
Danaher Corp., a significant player in the Pharmaceuticals & Biotechnology sector, has seen a valuation adjustment with its stock price at $190.79, reflecting a -4.79% return over the past year. The company's financial metrics include a P/E ratio of 41 and a dividend yield of 0.54%, indicating a competitive position but also challenges in growth compared to its peers like Abbott Laboratories and Thermo Fisher Scientific.
ABT Price History for Abbott Laboratories Stock
This article from Barchart.com provides a detailed price history for Abbott Laboratories (ABT) stock, including daily prices, latest trades, and corporate actions. It offers tools for members to download historical data, view 52-week key points, and analyze new highs and lows over various periods. The platform also outlines different membership levels and their associated data access and download capabilities.
ABT SEC Filings - Abbott Labs 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Abbott Labs (ABT) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms (Form 4). It includes AI-powered summaries to help investors understand key points from these regulatory documents, such as merger terms, blackout periods for employee benefit plans, and corporate governance updates. The platform tracks 77 SEC filings for ABT, with the most recent one filed on July 1, 2025.
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $122
Wells Fargo has reiterated its Buy rating for Abbott Laboratories (ABT.US) and maintained its price target of $122. This suggests a continued positive outlook on the company's stock performance from the financial institution.
ABT SEC Filings - Abbott Labs 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Abbott Labs (ABT) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It offers access to official regulatory documents from the U.S. Securities and Exchange Commission, with AI-powered summaries to help investors understand key points like merger terms, benefit plan blackout periods, and board changes. The article details recent filings, including Q3 2025 earnings, 8-K reports on financial results and non-GAAP measures, and several Form 4 insider transaction reports.
Compagnie Lombard Odier SCmA Makes New Investment in Abbott Laboratories $ABT
Compagnie Lombard Odier SCmA recently purchased 675,058 shares of Abbott Laboratories (NYSE:ABT) valued at approximately $84.6 million in the fourth quarter, making it their 25th largest holding. Abbott reported Q4 EPS in line with expectations but missed revenue targets, setting FY 2026 EPS guidance between $5.55 and $5.80. The company faces mixed analyst sentiment, with a consensus "Moderate Buy" rating, and is engaged in strategic developments while paying a quarterly dividend.
Bank Pictet & Cie Europe AG Decreases Position in Abbott Laboratories $ABT
Bank Pictet & Cie Europe AG significantly reduced its stake in Abbott Laboratories, selling over 13,000 shares in Q4, with its remaining holdings valued at $7.52 million. This move comes as Abbott reported mixed Q4 results, meeting EPS estimates but missing revenue, while providing Q1 and FY2026 guidance and announcing a quarterly dividend. The article details strategic developments for Abbott, including an investment in Whoop and integration with Flatiron’s OncoEMR, alongside a mixed sentiment from analysts regarding its stock performance.
Banque Pictet & Cie SA Sells 83,130 Shares of Abbott Laboratories $ABT
Banque Pictet & Cie SA significantly reduced its stake in Abbott Laboratories by selling 83,130 shares, decreasing its holdings by 37.3%. Despite this, analyst sentiment remains generally positive, with a "Moderate Buy" consensus rating for Abbott Laboratories, even as some price targets have been trimmed. The company reported Q4 EPS in line with estimates but revenue slightly below expectations, and announced a quarterly dividend of $0.63.
Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves
William Blair initiated coverage on MiniMed Group Inc. (NASDAQ: MMED), highlighting its recovery story despite past competitive setbacks. The company, a unit of Medtronic Plc, is improving its product pipeline with new innovations like the MiniMed Flex, a next-generation insulin pump cleared by the FDA. Despite facing ongoing competition and profitability challenges, its valuation presents an attractive risk-reward profile for investors.
Abbott Laboratories (ABT)’s Libre Linked to Fewer Heart Hospitalizations in Diabetes
Abbott Laboratories' FreeStyle Libre continuous glucose monitoring system has been linked to a reduction in heart hospitalizations among diabetes patients, according to new research presented at the American College of Cardiology's Annual Scientific Session. This positive outcome further highlights the health benefits of the device. The study's findings are expected to contribute to the growing body of evidence supporting the use of continuous glucose monitoring in managing diabetes and related cardiovascular complications.
Assessing Abbott Laboratories (ABT) Valuation After New Flatiron Health Oncology Integration
Abbott Laboratories recently integrated its Precision Oncology testing portfolio with Flatiron Health's OncoEMR, enhancing its cancer diagnostics reach. Despite this expansion and other strategic moves, Abbott's share price performance has seen recent declines, though it appears undervalued by approximately 25% according to one narrative. The article suggests that while the company possesses strong fundamentals and growth potential, investors should consider potential risks like regulatory setbacks and competitive pressures before making investment decisions.
Reasons to Retain Abbott Stock in Your Portfolio Now
Abbott Laboratories (ABT) is expected to see growth driven by strong sales recovery in its Nutrition business, particularly the Ensure brand, and continued robust adoption of its FreeStyle Libre CGM system in Diabetes Care. However, the company faces headwinds from currency fluctuations and a challenging macroeconomic environment. Despite these challenges, Abbott's strategic initiatives in product innovation and expanded market reach for its Diabetes Care franchise position it for future growth.
The Evolution of a MedTech Giant: A Deep Dive into Becton, Dickinson and Company (BDX)
Becton, Dickinson and Company (BDX) has transformed into a "pure-play" medical technology entity after spinning off its Biosciences and Diagnostic Solutions unit and merging it with Waters Corporation. The company is now focused on medical delivery, interventional surgery, and connected care, aiming for high-margin software and automated systems. Despite past stock volatility and underperformance, BD’s financial profile shows strength, and it is positioned for growth through its focus on "Smart Connected Care" and addressing healthcare labor shortages and the aging population.
Key Factors and Emerging Trends Shaping the Implantable Neurostimulators Market Landscape
The implantable neurostimulators market is experiencing rapid growth, projected to reach $11.44 billion by 2030, driven by technological innovations, an aging population, and increased clinical validation. Key players like Abbott Laboratories and Medtronic plc are leading advancements, including next-generation rechargeable systems and personalized therapies for various neurological disorders. The market is segmented by product type, application, and end-use, with significant focus on devices like spinal cord stimulators and deep brain stimulators for conditions such as Parkinson's disease and chronic pain.
Top Players and Market Competition in the In Situ Hybridization Industry
The in situ hybridization market is projected to reach $3.08 billion by 2030, growing at an 11.3% CAGR, driven by personalized medicine, AI-driven analysis, and genomic research. Key players like Thermo Fisher Scientific and Danaher Corporation are shaping the industry, with a focus on innovations such as Hybridization Chain Reaction RNA Chromogenic in situ Hybridization (HCR RNA-CISH). The market is segmented by product types, techniques, probe types, applications, and end-users, highlighting its specialized and evolving nature.
Competitive Analysis: Key Market Leaders and New Entrants in the Lyme Disease Testing Industry
The Lyme disease testing market is projected to reach $16.46 billion by 2030, growing at a CAGR of 9.0%, driven by advancements in diagnostics and increased awareness of tick-borne illnesses. Key trends include AI-assisted tools, home-testing kits, and multi-disease panels. Companies like Roche, Thermo Fisher Scientific, and Quest Diagnostics are leading innovation, with strategic partnerships and technological advancements enhancing early and precise detection methods.
